All In Biotech

Drug Trial Radar · NCT07287982

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

May 28, 2029

Study completion May 28, 2029

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune system responds to it. The study consists of a double-blinded treatment period (DBTP) where participants will either receive ARGX-119 IV or placebo IV, in addition to disease-modifying therapy (DMT) for 24 weeks. Participants who complete the DBTP will enter the open-label active-treatment extension period (ATEP) during which all participants will receive ARGX-119 IV up to 100 weeks (approximately 2 years).

Conditions

  • Spinal Muscular Atrophy (SMA)

Interventions

  • ARGX-119 IVBiological

    Intravenous infusion of ARGX-119

  • Placebo IVOther

    Intravenous infusion of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEsTime frame: Up to 124 weeks
  2. Incidence of SAEsTime frame: Up to 124 weeks
  3. Change in RHS total score from baseline to week 24 of the double blinded treatment period (DBTP)Time frame: Up to 24 weeks

Locations

46 sites in 10 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Rady Childrens Hospital

    San Diego, California · Withdrawn

  • Stanford University Medical Center

    Stanford, California · Recruiting

  • Connecticut Children's Medical Center

    Hartford, Connecticut · Recruiting

  • Rare Disease Research FL LLC

    Kissimmee, Florida · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • University of Iowa Stead Family Children's Hospital

    Iowa City, Iowa · Recruiting

  • The Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • The Curators of the University of Missouri on behalf of University of Missouri Health Care

    Columbia, Missouri · Recruiting

  • Columbia University Herbert Irving Comprehensive Cancer Center

    New York, New York · Recruiting

  • Rare Disease Research NC, LLC

    Hillsborough, North Carolina · Recruiting

  • Children's Hospital Philadelphia - Neurology

    Philadelphia, Pennsylvania · Not yet recruiting

  • Neurology Rare Disease Center

    Flower Mound, Texas · Recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • Childrens Hospital of The Kings Daughters

    Norfolk, Virginia · Not yet recruiting

  • Sydney Children's Hospital, Randwick

    Randwick, New South Wales, Australia · Recruiting

  • Royal Children's Hospital

    Parkville, Victoria, Australia · Not yet recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Not yet recruiting

  • UZ Leuven

    Leuven, Belgium · Not yet recruiting

  • C. H. R. de la Citadelle

    Liège, Belgium · Not yet recruiting

  • University of Calgary - Alberta Children's Hospital

    Calgary, Alberta, Canada · Not yet recruiting

  • BC Children's Hospital

    Vancouver, British Columbia, Canada · Not yet recruiting

  • The Hospital for Sick Children

    Toronto, Ontario, Canada · Withdrawn

  • Universitaetsklinikum Essen

    Essen, Germany · Not yet recruiting

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, Germany · Not yet recruiting

  • Universitaetsklinikum Ulm

    Ulm, Baden-Wurttemberg, Germany · Not yet recruiting

  • Klinikum der Universitaet Muenchen

    München, Bavaria, Germany · Not yet recruiting

  • Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS

    Genova, Italy · Not yet recruiting

  • Azienda Ospedaliera Universitaria Policlinico G. Martino

    Messina, Italy · Not yet recruiting

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy · Not yet recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Not yet recruiting

  • Fondazione Serena Onlus - Centro Clinico Nemo

    Milan, Milano, Italy · Not yet recruiting

  • UMC Utrecht

    Utrecht, Netherlands · Not yet recruiting

  • Instytut Centrum Zdrowia Matki Polki

    Lodz, Poland · Not yet recruiting

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Poznan, Poland · Not yet recruiting

  • Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego

    Warsaw, Poland · Not yet recruiting

  • Hospital Universitari Vall d'Hebron - VHIR

    Barcelona, Spain · Not yet recruiting

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain · Not yet recruiting

  • Addenbrooke's Hospital

    Cambridge, Cambridgeshire, United Kingdom · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.